TScan Therapeutics, Inc. announced changes to its Board of Directors. Garry A. Nicholson has been appointed to the Company?s Board of Directors, effective as of June 12, 2024. Mr. Nicholson will serve as a Class I director until the date of the annual meeting of stockholders following the year ending December 31, 2024, or until his earlier death, resignation or removal.

The Board has determined that Mr. Nicholson qualifies as an independent director under the listing standards of the Nasdaq Global Market. In addition, Timothy Barberich has retired as a Member and Chair of the Board of Directors after the conclusion of the 2024 Annual Meeting of Stockholders held on June 12, 2024. Current board member Stephen Biggar, M.D., Ph.D., will assume the role of Chair of the Board of Directors, effective as of June 12, 2024.

Dr. Biggar will no longer serve on the Nominating and Corporate Governance Committee, but he will continue in his positions as a Class I director of the Board and Chairman of the Compensation Committee of the Board. Mr. Nicholson will serve on the Nominating and Corporate Governance Committee of the Board and on the Research and Clinical Development Committee of the Board. Effective as of the Effective Date, the Nominating and Corporate Governance Committee of the Board is composed of Katina Dorton, Gabriela Gruia and Garry Nicholson and the Research and Clinical Development Committee of the Board is composed of Barbara Klencke, Gabriela Gruia, Stephen Biggar and Garry Nicholson.

The compositions of the Audit Committee and the Compensation Committee of the Board remain unchanged. Mr. Nicholson has more than 35 years of pharmaceutical and biotech oncology experience. Mr. Nicholson currently serves as chairman of the board of directors for G1 Therapeutics, Day One Biopharmaceuticals and Abdera Therapeutics.

He also previously served on the board of directors for Turning Point Therapeutics, Five Prime Therapeutics, Tmunity and TESAROprior to their acquisitions by large pharmaceutical companies. As former president of Pfizer Oncology, his responsibilities included global commercialization, sales, clinical development, regulatory strategy and business development for Pfizer?s oncology portfolio. Earlier in his career, Mr. Nicholson held various leadership positions in the oncology division of Eli Lilly and Company, including global oncology platform leader.

He has also served as president and CEO of XTuit Pharmaceuticals. Mr. Nicholson earned a B.S. in Pharmacy from the University of North Carolina at Chapel Hill and an M.B.A. from the University of South Carolina.